The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
REGULATORY
CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
Japan is to not use its new cost-effectiveness assessment (CEA) scheme for reimbursement decisions - at least for now - but this would give no respite for the industry as budget examiner Iichiro Yoshino says the Ministry of Finance’s (MOF)…
To read the full story
Related Article
- Ensuring Patient Access Was MHLW’s Top Priority for CEA Scheme: Policy Planning Director
April 23, 2019
- With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
April 5, 2019
- Ex-Minister Tamura: 3 New Sources of Social Security Funding Needed to Stem Overreliance on Drug Price Cuts
April 3, 2019
- Kyokai Kenpo Director Yoshimori: Japan Should Eventually Use Cost-Effectiveness Assessment to Set Launch Prices
March 29, 2019
- Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
- JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary
March 7, 2019
REGULATORY
- Nitrosamine Detected in Sumitomo’s Arotinolol, but No Recall Planned
March 28, 2025
- Choseido’s Kawauchi Plant Suspended for 1 Month on GMP Violation
March 28, 2025
- Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More
March 28, 2025
- Japan Won’t Ban Red No. 3 for Now but Asks Industry for Self-Inspections
March 27, 2025
- It’s Time to Review Conditional Approval System for Regenerative Medicines: MHLW Official
March 27, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…